Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Favorite

Scientific Oral Presentations

Laryngology/Broncho-Esophagology

Session: Scientific Oral Presentation 3 - Laryngology/Broncho-Esophagology

A Novel Implementation of Placentally-Derived Connective Tissue Matrix in Laryngotracheal Stenosis

Monday, October 13, 2025

9:42 AM - 9:48 AM EDT

Location: 138

Disclosure(s):

Sunjay S. Anekal, Other:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Ananya Tadikonda, Other:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Stacey L. Halum, MD, FACS:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Introduction: Airway stenosis is a challenging clinical problem, often managed with airway dilation and adjuvant therapy. Placenta-derived connective tissue matrix (pdCTM) [CTM Flow™, CTM Biomedical®, Lake Worth, Florida] has not been previously described as an adjuvant therapy but warrants investigation because of its regenerative properties.

Methods: A cytokine array (C1000 Cytokine Array, AAH-CYT-1000-2, RayBiotech, Peachtree Corners, Georgia) was used to identify anti-inflammatory and anti-fibrotic proteins in pdCTM. A single-institution retrospective chart review study was conducted. After excluding pediatric and tracheostomy-dependent patients, 121 patients who underwent 385 airway dilation procedures from 1/1/2015-present (set as 1/19/2025) were identified. Procedure type, location of stenosis (subglottic/tracheal, supraglottic/glottic), adjuvant therapy, and dilation intervals were analyzed. Dilation intervals between adjuvant versus no adjuvant therapies were compared using an unpaired two-tailed T-test. Because pdCTM is a newly available product, pdCTM dilation intervals were compared to adjuvant treatment dilation intervals within the same treatment time frame using an unpaired one-tailed T-test.

Results: Multiple anti-inflammatory (IL-1ra) and anti-fibrotic (bFGF, TIMP-2, TGF-β3) proteins were identified in pdCTM. Analysis of individual dilations showed no difference in dilation intervals between the adjuvant therapy group [641 days (n = 344)] versus the non-adjuvant therapy group [801 days (n = 41)](p = 0.184). With respect to subsites, the subglottic/tracheal stenoses showed no increase in dilation intervals when adjuvant therapy was administered (p = 0.954). When pdCTM was compared with other adjuvant therapies administered during the same period (from 6/19/2023-1/19/2025), the average time between dilation was 503 days (n = 9) for the pdCTM group and 368 days (n = 9) for the non-pdCTM groups (p < 0.01).

Conclusions: While traditional adjuvant therapies fail to demonstrate consistent benefits, early findings suggest pdCTM to be a promising new option.

Presenting Author(s)

Sunjay S. Anekal, Other

Medical Student
Indiana University School of Medicine
Indianapolis, IN, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Ananya Tadikonda, Other

Medical Student
IU School of Medicine
Indianapolis, IN, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Co-Author(s)

Gabe G. Sobczak, MD

Physician Resident
Indiana University School of Medicine
Indianapolis, IN, United States

Disclosure information not submitted.
TW

Troy Wesson, Other

IUSM, United States

Disclosure information not submitted.
Lena W. Chen, MD

Resident
Indiana University School of Medicine
Indianapolis, IN, United States

Disclosure information not submitted.
Patrick R. Finnegan

Laboratory Director; Research Scientist
Indiana University School of Medicine
Indianapolis, IN, United States

Disclosure information not submitted.

Senior Author(s)

Stacey L. Halum, MD, FACS

Professor
Indiana University School of Medicine
Indianapolis, IN, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.